BRCA1 and ovarian carcinoma: The pooled analysis of 50 ovarian cancer patients with BRCA1/2-mutation treated on phase I and II studies (11 on phase I, and 39 on phase phase II receiving olaparib 200 mg twice daily) showed RR of 40% and DCR of 46%, predominately in platinum-sensitive group [108].